Home
Faculty Directory
Niraj K. Shenoy, M.D., Ph.D., M.S.

Niraj K. Shenoy, M.D., Ph.D., M.S.

Assistant Professor, Department of Medicine (Oncology)

Contact Information

718.430.4056niraj.shenoy@einsteinmed.org

Albert Einstein College of Medicine
Jack and Pearl Resnick Campus
1300 Morris Park Avenue
Chanin Building, Room 302A
Bronx, NY 10461

Research Profiles

More Resources: NLM- list of published work

Is this your profile? Edit profile

Professional Interests

Physician-Scientist.

Principal Investigator, Shenoy Lab, Albert Einstein Cancer Center. Attending Physician, Medical Oncology, Montefiore (GU Oncology, with a focus on kidney cancer).

Interests

Basic/ Translational/ Clinical Cancer research: Interactions between driver pathways, metabolism, epigenetics and immune evasion; Cancer biology; DNA methylation in cancer; Experimental Therapeutics; Early phase clinical trials

Clinical Medicine: Clinical Oncology (Genitourinary malignancies); Clinical Internal Medicine

Teaching (medical students/ residents/ clinical and post-doctoral fellows)

Ethics in Academia

A. Understanding and targeting epigenetic dysregulation, aberrant metabolism, and immune evasion in cancer

Aggarwal RK, Zou Y, Luchtel RA, Pradhan K, Ashai N, Ramachandra N, Albanese J, Yang J, Wang X, Aluri S, Gordon S, Machha V, Tischer A, Aboumohamed A, Gartrell B, Hafizi S, Pullman J, Shenoy N*. Functional succinate dehydrogenase deficiency and loss of ascorbic acid transporter SLC23A1 are pathognomonic adverse features of clear cell renal cancer. Preprint at Biorxiv (https://www.biorxiv.org/content/10.1101/2020.07.05.188433v2). *corresponding
Luchtel RA, Bhagat T, Pradhan K, Jacobs WR, Levine M, Verma A, Shenoy N*. High-dose Ascorbic acid synergizes with anti-PD1 in a Lymphoma mouse model. Proc Natl Acad Sci U S A. 2020 Jan 7. pii: 201908158. doi: 10.1073/pnas.1908158117. [Epub ahead of print] PMID: 31911474. *corresponding
Shenoy N*, Bhagat TD, Cheville JC, Lohse C, Bhattacharyya S, et al. Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcystosine loss in renal cell carcinoma. J Clin Invest 2019 Mar 4;130:1612-1625. PMID: 30702441. *co-corresponding (JCI Editor's pick, April 2019 issue)
Shenoy N*, Creagan E, Witzig T, Levine M. Ascorbic acid in cancer treatment: Let the phoenix fly. Cancer Cell. 2018 Nov 12;34(5):700-706.(Review) PMID: 30174242. *co-corresponding
Shenoy N*, Bhagat T, Nieves E, Stenson M, Lawson J, et al. Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells. Blood Cancer J. 2017 Jul 21;7(7): e587. PMID: 28731456. *co-corresponding
Shenoy N*. Epigenetic dysregulation by aberrant metabolism in renal cell carcinoma can be reversed with Ascorbic acid. Mol Cell Oncol. 3 April 2019. PMID: 31131312. *corresponding

B. Kidney cancer translational research

Shenoy N*, Bhagat TD, Cheville JC, Lohse C, Bhattacharyya S, et al. Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcystosine loss in renal cell carcinoma. J Clin Invest 2019 Jan 31. pii: 98747. doi: 10.1172/JCI98747. PMID: 30702441. *co-corresponding
Shenoy N*. HIF1α is not a target of 14q deletion in clear cell renal cancer. Sci Rep 2020 Oct 19;10(1):17642. PMID: 33077781. *corresponding
Wang X, Lopez R, Luchtel RA, Hafizi S, Gartrell B, Shenoy N*. Immune evasion in renal cell carcinoma: biology, clinical translation, future directions. Kidney Int 2020 Sep 17;S0085-2538(20)31078-4. *corresponding
Shenoy N*, Pagliaro L: Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective. Ann Oncol 2016 Sep;27(9):1685-95. PMID: 27329246. *corresponding
Shenoy N*, Vallumsetla N, Galeas JN, Shrivastava M, Hu C, et al. Role of DNA Methylation in Renal Cell Carcinoma. J Hematol Oncol 2015 Jul 22;8:88. PMID: 26198328. *co-corresponding
Shenoy N*, Shrivastava M, Sukrithan V, Papaspyridi D, Darbinyan K. The Regulation and Interactions of the Hypoxia Inducible Factor Pathway in Carcinogenesis and Potential Cancer Therapeutic Strategies. J Cancer Ther 2015 Jun;6 (06): 511-521. *corresponding
Hu CY, Mohtat D, Yu YA, Ko Y, Shenoy N, et al. Kidney cancer is characterized by aberrant methylation of tissue specific enhancers that are prognostic for overall survival. Clin Can Res 2014 Aug 15;20(16):4349-60. PMID: 24916699.
Shenoy N* et al. Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning? Clin Genitourin Cancer. 2018 Jun 28. PMID: 30077464. *co-corresponding
Shenoy N*, Pagliaro L. Re: Targeting Renal Cell Carcinoma with a HIF-2 Antagonist. Eur Urol. 2018 Feb;73(2):304-305 Words of Wisdom section. PMID: 29102314. *corresponding
Shenoy N*. Epigenetic dysregulation by aberrant metabolism in renal cell carcinoma can be reversed with Ascorbic acid. Mol Cell Oncol. 3 April 2019. PMID: 31131312. *corresponding
Aggarwal RK, Zou Y, Luchtel RA, Pradhan K, Ashai N, Ramachandra N, Albanese J, Yang J, Wang X, Aluri S, Gordon S, Machha V, Tischer A, Aboumohamed A, Gartrell B, Hafizi S, Pullman J, Shenoy N*. Functional succinate dehydrogenase deficiency and loss of ascorbic acid transporter SLC23A1 are pathognomonic adverse features of clear cell renal cancer. Preprint at Biorxiv (https://www.biorxiv.org/content/10.1101/2020.07.05.188433v2). *corresponding

C. Ethics in Academia

Shenoy N*. Professional Ethics in Academia: defining the categories of behavior spectrum in matters of unethical conduct. International Journal of Ethics Education (2019), official journal of the International Association for Education in Ethics- a UNESCO initiative. https://doi.org/10.1007/s40889-019-00071-1 *corresponding

Other publications listed below

Active Clinical Trial Protocols:

1. Randomized phase II trial of High Dose Intravenous Ascorbic Acid as an Adjunct to Azacytidine in Higher-Risk Myelodysplastic Syndromes

Role: PI and wrote the protocol. Status: pending regulatory approvals

2. Randomized phase II trial of Intravenous Ascorbic acid as an adjunct to pazopanib for metastatic and unresectable clear cell renal cell carcinoma (ccRCC): A study of Academic and Community Cancer Research United (ACCRU) GU1703.

Role: Co-PI and wrote the protocol. Clinicaltrials.gov Identifier: NCT03334409. Status: open to accrual

https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.7_suppl.TPS679

3. Phase II Trial of High Dose Intravenous Ascorbic Acid as an Adjunct to Salvage Chemotherapy in Relapsed / Refractory Lymphoma

Role: Co-PI and wrote the protocol. Clinicaltrials.gov Identifier: NCT03418038. Status: open to accrual

Medical Education and Training:

Medical school: Bangalore Medical College and Research Institute, India

Residency: Internal Medicine, Albert Einstein College of Medicine/ Jacobi Medical Center, NY, USA

Chief Residency: Internal Medicine, Albert Einstein College of Medicine/ Jacobi Medical Center, NY, USA

Fellowship: Hematology and Oncology, Mayo Clinic Rochester, MN, USA

Master of Science (Clinical Research): Drexel University College of Medicine, PA, USA

Doctor of Philosophy (PhD): Dept of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK

Thesis: Understanding and targeting epigenetic dysregulation, aberrant metabolism, and immune evasion in cancer with ascorbic acid

Viva dissertation defense examiners’ institutions: University of Birmingham (external 1), University of Wolverhampton (external 2), University of Portsmouth (internal)

Select Honors/ Awards:

American Cancer Society Research Scholar Grant award

American Society for Clinical Investigation Young Physician Scientist award

Selection as a Paul Calabresi K12 Scholar at Einstein/ Montefiore (highest score). Transitioned to independent investigator prior to formal enrollment in the Calabresi program.

American Society of Hematology Research Award for Fellows

National Cancer Institute SPORE Development Research Project Award

Mayo Clinic William H.J. Summerskill Award (highest fellowship honor, Mayo Clinic School of Graduate Medical Education)

Winner, Mayo Clinic Young Investigators Research Symposium

American Federation for Medical Research Henry Christian Award

Leo. M. Davidoff society of the Albert Einstein College of Medicine Recognition Award for teaching excellence

Gold medal, Medicine, Bangalore Medical College & Research Institute

American Board Certifications:

Internal Medicine; Medical Oncology; Hematology

Selected Publications

Shenoy N*. HIF1α is not a target of 14q deletion in clear cell renal cancer. Sci Rep 2020 Oct 19;10(1):17642. PMID: 33077781
Shenoy N*. Aggressive myoepithelial carcinoma with EWSR1-POU5F1 fusion highly responsive to Ewing sarcoma combination chemotherapy. Cancer 2020 Oct 13. PMID: 33048366
Wang X, Lopez R, Luchtel RA, Hafizi S, Gartrell B, Shenoy N*. Immune evasion in renal cell carcinoma: biology, clinical translation, future directions. Kidney Int 2020 Sep 17;S0085-2538(20)31078-4. PMID: 32949550
Shenoy N*, Luchtel R, Gulani P. Considerations for target oxygen saturation in COVID-19 patients: are we under-shooting? BMC Med. 2020 Aug 19;18(1):260 PMID: 32814566
Aggarwal RK, Zou Y, Luchtel RA, Pradhan K, Ashai N, Ramachandra N, Albanese J, Yang J, Wang X, Aluri S, Gordon S, Machha V, Tischer A, Aboumohamed A, Gartrell B, Hafizi S, Pullman J, Shenoy N*. Functional succinate dehydrogenase deficiency is a pathognomonic adverse feature of clear cell renal cancer. Preprint at Biorxiv (https://www.biorxiv.org/content/10.1101/2020.07.05.188433v1). *corresponding
Luchtel RA, Bhagat T, Pradhan K, Jacobs WR, Levine M, Verma A, Shenoy N*. High-dose Ascorbic acid synergizes with anti-PD1 in a Lymphoma mouse model. Proc Natl Acad Sci U S A. 2020 Jan 7. PMID: 31911474.
Shenoy N*. Epigenetic dysregulation by aberrant metabolism in renal cell carcinoma can be reversed with Ascorbic Acid. Mol Cell Oncol 3 April 2019. PMID: 31131312
Shenoy N*. Professional Ethics in Academia: defining the categories of behavior spectrum in matters of unethical conduct. Int J Ethics Educ 15 April 2019. DOI: https://doi.org/10.1007/s40889-019-00071-1
Shenoy N*, Bhagat T, Verma A et al. Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcystosine loss in renal cell carcinoma. J Clin Invest 2019 Mar 4;130:1612-1625. PMID: 30702441.
Shenoy N*, Levine M et al. Ascorbic acid in Cancer treatment: Let the Phoenix Fly. Cancer Cell. 2018 Nov 12;34(5):700-706. PMID: 30174242 . doi: 10.1016/j.ccell.2018.07.014.
Shenoy N*, Pagliaro L, Begna K et al. Association between Renal cell carcinoma and Myelodysplastic syndromes. Clin Genitourin Cancer. 2018 Jun 28. PMID: 30077464
Shenoy N*, Pagliaro L. Increased expression of HIF-1α in HIF-2 antagonist resistant clear cell Renal Cell Carcinoma- relevance for translation? Invited submission to the ‘Words of Wisdom’ section, Eur Urol. 2018 Feb;73(2):304-305.
Shenoy N*, Pagliaro L, Witzig T et al. Low HIF-1alpha expression in testicular GCT- a major reason for enhanced chemosensitivity? Chin J Cancer Res. 2017 Aug; 29(4): 374–378.
Shenoy N*, Verma A, Witzig T et al. Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells. Blood Cancer J 2017 Jul 21;7(7): e587. PMID: 28731456.
Barbosa N, Wetter D, Wieland C, Shenoy N, Markovic S, Thanarajasingam et al. Scleroderma induced by Pembrolizumab: a case seires. Mayo Clinic Proceedings. 2017
Shenoy N*. Link between dysregulated hypoxia signaling and aberrant methylation in Clear Cell Renal Cell Carcinoma? Chin J Cancer Res 2017 Apr; 29(2): 166–167
Shenoy N*, Stenson M, Lawson J, Abeykoon J, Patnaik M, Wu X, Witzig T. Drugs with anti-oxidant properties can interfere with cell viability measurements by assays that rely on the reducing property of viable cells. Nature’s Laboratory Investigation. 2017 Feb 27. (Epub ahead of print)
Bhagat T, Zou Y, Huang S, Park J, Palmer MB, Hu C, Li W, Shenoy N, Verma A, Susztak K, et al. Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer. J Biol Chem. 2016 Dec 1, 837-846.
Shenoy N, Kohli M. Role of Systemic Chemotherapy in Metastatic Hormone-sensitive Prostate Cancer. Indian J Urol; 2016 Oct-Dec; 32(4):257-261.
Haddox CL^, Shenoy N^, Kao JC, Shah KK, Jain S, Halfdanarson TR, Wijdicks EF, Goetz MP ^{^}contributed equally. Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm. Ann Oncol . 2016 Dec 19. 28(3): 673–675
Wang Y, Lieberman R, Pan J, Zhang Q, Du M, Zhang P, Kohli M, Shenoy N, Wang L, et al. MiR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Mol Cancer. 2016 Nov 10;15(1):70
Shenoy N*, Markovic S et al. Pembrolizumab induced severe sclerodermoid reaction. Ann Oncol. 2016 Oct 13. 28(2) 432-33
Shenoy N*, Pagliaro L. Sequential Pathogenesis of Metastatic VHL mutant Clear Cell Renal Cell Carcinoma: putting it together with a translational perspective. Ann Oncol 2016 Sep;27(9):1685-95
Xia Y, Huang CC, Dittmar R, Du M, Wang Y, Liu H, Shenoy N, Wang L, Kohli M. Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer. Oncotarget. 2016 Apr 26. 7(24):35818-35831
Shenoy N*, Tesfaye M, Brown J, Simmons N, Weiss D, Meholli M, Mabie P. A case of Steroid Resistant Bulbar Neurosarcoidosis responsive to Intravenous immunoglobulin.Pract Neurol;15(4): 289-292
Shenoy N*. Is ADRM1 a good target for cancer therapy? Acta Haematol. 2015;134(2):86-7
Shenoy N*, Vallumsetla N, Verma A. et al. Role of DNA methylation in Renal Cell Carcinoma. J Hematol Oncol 2015 Jul 22; 8:88
Shenoy N*, Shrivastava M, et al. The Regulation and Interactions of the Hypoxia Inducible Factor Pathway in Carcinogenesis and Potential Cancer Therapeutic Strategies. J Cancer Ther 2015 Jun;6 (06): 511-521
Shrivastava MS, Hussain Z, Giricz O, Shenoy N, Polineni R, Maitra A, Verma A.Targeting Chemokine Pathways in Esophageal Adenocarcinoma.Cell cycle 2014;13(21):3320-7
Hu C, Mohtat D, Yu Y, KoY, Shenoy N, Verma A, et al.Kidney cancer is characterized by aberrant methylation of tissue specific enhancers that are prognostic for overall survival. Clin Cancer Res 2014 Aug 15;20(16):4349-60
Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y. Impact of Iron overload and potential benefit from Iron chelation in Low-risk MDS. Blood. 2014 Aug 7;124(6):873-81
Rishikesh K, Kini U, Shenoy N, Joy B, D’Souza G, Shet A. Malignant Pleural Mesothelioma. J Assoc Physicians India. 2013 Aug;61(8):576-9
Barta SK, Zou Y, Schindler J, Shenoy N, Bhagat TD, Steidl U, Verma A. Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia. Leuk Lymphoma. 2012 Oct;53(10):1999-2003
Shenoy N, Kessel R, Bhagat TD, Bhattacharyya S, Yu Y, McMahon C, Verma A. Alterations in the ribosomal machinery in cancer and hematological disorders. J Hematol Oncol. 2012 Jun 18;5:32
Shenoy N, Prabhakar SM. Finasteride and Male Breast Cancer- does the MHRA report show a link?J. Cutan Aesthet Surg. 2010 May; 3(2):102-5

Original Protocol: Shenoy N* et al: Protocol modification to determine the cytotoxic potential of drugs using cell viability assays that rely on the reducing property of viable cells. Invited submission to Protocol Exchange (nature.com) doi: 10.1038/protex.2017.029

* corresponding author

Full list of publications:

NLM: https://www.ncbi.nlm.nih.gov/sites/myncbi/10QhumtgctGA9/bibliography/48213834/public/?sort=date&direction=ascending

Google Scholar: http://scholar.google.com/citations?user=fLDouWAAAAAJ&hl=en

ORCID Id: 0000-0003-2074-1108